新型抗生素与通用抗生素治疗医院获得性及呼吸机相关性细菌性肺炎的疗效与安全性:随机对照试验的系统综述与Meta分析
该系统综述纳入8项RCT共2881例HABP/VABP患者,比较新型抗生素与通用抗生素。Meta分析显示两组28天全因死亡率、临床应答和微生物学应答均无显著差异,但新型抗生素较含黏菌素方案显著降低肾毒性,且对碳青霉烯耐药革兰阴性杆菌的微生物学清除率显著更优。
要点
- 新型与通用抗生素治疗HABP/VABP的28天死亡率、临床和微生物学应答无显著差异。
- 新型抗生素较含黏菌素方案显著降低肾毒性(RR 0.30)。
- 新型抗生素对碳青霉烯耐药革兰阴性杆菌的微生物学清除率显著更优(RR 1.50)。
核心结论
- 新型抗生素与通用抗生素治疗HABP/VABP的疗效和安全性总体相似。
- 新型抗生素在碳青霉烯耐药革兰阴性杆菌的微生物学清除方面显示优势。
研究设计与样本
- 系统综述与Meta分析,检索2013至2025年多个数据库的RCT(注册号CRD42023476481)。
- 纳入8项RCT,共2881例HABP/VABP患者,新型抗生素组1450例,通用抗生素组1431例。
主要发现
- 亚组分析中,新型抗生素对碳青霉烯耐药革兰阴性杆菌的微生物学清除率显著更优(RR 1.50,95%CI 1.18-1.90,I2=0%)。
临床怎么用
- 在HABP/VABP经验性治疗中,新型抗生素与通用抗生素疗效相当,需结合本地耐药流行病学选择。
- 对于碳青霉烯耐药革兰阴性杆菌感染,新型抗生素可能提高微生物学清除率。
- 需使用含黏菌素方案时,新型抗生素可减少肾毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), particularly cases caused by multidrug-resistant organisms, often require newer antibiotic treatment. The efficacy and safety of newer antibiotics compared with generic antibiotics in randomized controlled trials (RCTs) have not been evaluated before. METHODS: In this systematic review, we searched RCTs in the United States National Library of Medicine (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, Ovid MEDLINE, ClinicalTrials.gov, and Google Scholar databases published between 2013 and 2025 (registration no. CRD42023476481). The primary efficacy end point was the 28-day all-cause mortality rate, and the secondary efficacy end points were clinical and microbiological response. The safety end point was nephrotoxicity. RESULTS: We identified 8 eligible RCTs involving 2881 patients with HABP/VABP (1450 treated with newer antibiotics and 1431 treated with generic antibiotics). The meta-analysis did not reveal any significant differences between newer and generic antibiotics in the 28-day all-cause mortality rate (risk ratio [RR], 0.97; 95% confidence interval [CI], .72-1.30; I2 = 30%), the clinical response (1.04 [.93-1.17]; I2 = 35%), or the microbiological response (1.05 [.89-1.24]; I2 = 52%). However, newer antibiotics showed significant lower occurrences of nephrotoxicity than regimens with a colistin component (RR, 0.30 [95% CI, .11-.79]; I2 = 0%). In the subgroup analysis, newer antibiotic regimens demonstrated significant improvement in microbiological eradication of carbapenem-resistant gram-negative bacilli (RR, 1.50 [95% CI, 1.18-1.90]; I2 = 0%). CONCLUSIONS: Newer antibiotics and generic drugs showed similar efficacy and safety in treating HABP/VABP. The superiority of newer antibiotics in the microbiological eradication of carbapenem-resistant gram-negative bacilli could suggest that future trials should be targeted to those patients to improve understanding of the therapeutic use of these antibiotics and the pathophysiology of these conditions.
引用
- Nguyen ATK, Paterson DL, Mo Y, et al. Efficacy and Safety of Newer Antibiotics Versus Generic Antibiotics for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Infect Dis. 2026. PMID: 42227056. doi:10.1093/cid/ciag045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。